eligibility_summary
Adults (≥18) with B‑cell NHL (DLBCL/PMBCL/HGBCL/FL incl. transformed) after SOC CD19 CAR‑T (axi‑cel/tisa‑cel/liso‑cel), day‑30 PET shows response but suboptimal (Deauville ≥3 or MRD+), ECOG 0–2, adequate counts (ANC ≥0.75, Hgb ≥8, Plt ≥50), renal (eGFR ≥45, CrCl >60), hepatic (bili ≤1.5×ULN, AST/ALT ≤3×ULN), QTcF <470, tissue for MRD, able to swallow, contraception. Excludes pregnancy, uncontrolled CV/neurologic disease, non‑protocol CAR‑T, strong CYP3A inhibitors/inducers, recent investigational agents.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, single-arm, dose-escalation trial of early, risk-adapted golcadomide (CC-99282) plus rituximab in adults with relapsed/refractory B‑cell NHL who have a sub‑optimal ~30‑day response after CD19 CAR‑T. Drugs/mechanisms: Golcadomide is an oral cereblon E3 ubiquitin ligase modulator (CELMoD, immunomodulatory agent) that binds CRBN to induce proteasomal degradation of IKZF1/IKZF3, enhancing T- and NK-cell activation and cytokine production, inhibiting B-cell survival, and potentiating antibody-dependent cytotoxicity. Rituximab is a chimeric anti‑CD20 monoclonal antibody depleting CD20+ B cells via complement-dependent cytotoxicity, ADCC, and apoptosis. Targets: CD20+ malignant B cells, cereblon/IKZF pathway, effector T and NK cells (including CD19 CAR‑T expansion/persistence), tumor microenvironment.